Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more
Allergy Therapeutics plc (AGYTF) - Total Liabilities
Latest total liabilities as of June 2025: $131.43 Million USD
Based on the latest financial reports, Allergy Therapeutics plc (AGYTF) has total liabilities worth $131.43 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Allergy Therapeutics plc - Total Liabilities Trend (2002–2025)
This chart illustrates how Allergy Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Allergy Therapeutics plc Competitors by Total Liabilities
The table below lists competitors of Allergy Therapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Multicampus Corporation
KQ:067280
|
Korea | ₩84.43 Billion |
|
Haulotte Group SA
PA:PIG
|
France | €404.55 Million |
|
ATA Creativity Global
NASDAQ:AACG
|
USA | $403.71 Million |
|
Thai Optical Group Public Company Limited
BK:TOG
|
Thailand | ฿2.15 Billion |
|
KSP Co. Ltd.
KQ:073010
|
Korea | ₩58.41 Billion |
|
Chia Her Industrial Co Ltd
TW:1449
|
Taiwan | NT$4.11 Billion |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
Korea | ₩160.29 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Allergy Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allergy Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allergy Therapeutics plc (2002–2025)
The table below shows the annual total liabilities of Allergy Therapeutics plc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $131.43 Million | +115.04% |
| 2024-06-30 | $61.12 Million | -5.54% |
| 2023-06-30 | $64.70 Million | +83.90% |
| 2022-06-30 | $35.18 Million | -11.05% |
| 2021-06-30 | $39.55 Million | -6.80% |
| 2020-06-30 | $42.44 Million | +37.18% |
| 2019-06-30 | $30.94 Million | +10.57% |
| 2018-06-30 | $27.98 Million | +2.81% |
| 2017-06-30 | $27.22 Million | +3.27% |
| 2016-06-30 | $26.36 Million | +62.38% |
| 2015-06-30 | $16.23 Million | +21.82% |
| 2014-06-30 | $13.32 Million | -6.79% |
| 2013-06-30 | $14.29 Million | +8.59% |
| 2012-06-30 | $13.16 Million | -53.79% |
| 2011-06-30 | $28.48 Million | +12.89% |
| 2010-06-30 | $25.23 Million | -44.25% |
| 2009-06-30 | $45.25 Million | +31.27% |
| 2008-06-30 | $34.47 Million | +123.88% |
| 2007-06-30 | $15.40 Million | +197.37% |
| 2006-06-30 | $5.18 Million | -21.26% |
| 2005-06-30 | $6.58 Million | +58.15% |
| 2004-06-30 | $4.16 Million | -25.78% |
| 2003-06-30 | $5.60 Million | -60.20% |
| 2002-06-30 | $14.07 Million | -- |